Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Chemed Corporation's management recently their financial results for the first quarter of 2024, which ended on March 31, 2024.</li><li>The earnings showed mixed results, with strong performance from VITAS and weaker metrics from Roto-Rooter.</li><li>VITAS, Chemed's healthcare subsidiary, showcased a robust operating performance with an increase in admissions of 4.5% over the previous year.</li></ul>

Chemed Corporation's management recently their financial results for the first quarter of 2024, which ended on March 31, 2024.The earnings showed mixed results, with strong performance from VITAS and weaker metrics from Roto-Rooter.VITAS, Chemed's healthcare subsidiary, showcased a robust operating performance with an increase in admissions of 4.5% over the previous year.

Chemed Corporation: A Tale Of Workforce & Patient Expansion To Catalyze Growth! - Major Drivers

<ul><li>Chemed Corporation reported their fourth quarter 2023 earnings with continued improvement in their VITAS operational metrics, including a 7% increase in admissions over the prior year period and an average daily census of 1,918.</li><li>This is an 11% increase in comparison to the prior year and suggests that a hiring and retention program initiated in 2022 to remedy any potential worker turnover and expand clinical workforce capacity has been successful in maintaining VITAS' operational performance.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Chemed Corporation reported their fourth quarter 2023 earnings with continued improvement in their VITAS operational metrics, including a 7% increase in admissions over the prior year period and an average daily census of 1,918.This is an 11% increase in comparison to the prior year and suggests that a hiring and retention program initiated in 2022 to remedy any potential worker turnover and expand clinical workforce capacity has been successful in maintaining VITAS' operational performance.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Duplicate of Tenet Healthcare Corporation: Initiation Of Coverage - Its Focus on Higher Acuity Services in Hospitals & Other Core Strategies! - Major Drivers

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Select Medical Holdings / Technical Analysis

<ul>
<li>We are starting to see some positive signals that suggest the lows for this bear market may have already been established, or that additional downside is limited from here.</li>
<li>We need to see downtrend reversals (get above 4030-4040 on SPX, $189 on IWM, and $115 on IWC) and for the NDX(QQQ) to break above $315, to get more constructive.</li>
<li>Positive signals include, among other things: the Financial Sector (XLF) and Broker-Dealers/Exchanges ETF (IAI) are reversing topside their 4-5-month downtrends.</li>
</ul>


We are starting to see some positive signals that suggest the lows for this bear market may have already been established, or that additional downside is limited from here.
We need to see downtrend reversals (get above 4030-4040 on SPX, $189 on IWM, and $115 on IWC) and for the NDX(QQQ) to break above $315, to get more constructive.
Positive signals include, among other things: the Financial Sector (XLF) and Broker-Dealers/Exchanges ETF (IAI) are reversing topside their 4-5-month downtrends.


Downgrading Utilities & Staples to Market Weight; Buy Ideas in Health Care & Trucking

Quality-first, Business-perspective Strategy, Urbem (HK) Limited

Steven Chen

Quality-first, Business-perspective Strategy

<ul data-v-2d66ea9f="">
<li data-v-2d66ea9f="">We like to regard managers of our (partially) owned companies as trusted partners, and therefore, look for owner-oriented stewards that treat shareholders fairly;</li>
<li data-v-2d66ea9f="">We present some easy-to-grasp gimmicks that can be leveraged to gauge this factor.</li>
</ul>


We like to regard managers of our (partially) owned companies as trusted partners, and therefore, look for owner-oriented stewards that treat shareholders fairly;
We present some easy-to-grasp gimmicks that can be leveraged to gauge this factor.


Some Easy-To-Grasp Gimmicks to Gauge Management Compensation

<p>Continued encouraging COVID-19 news and accommodative moves by the Fed have allowed the bulls to remain in control while short-term support on the S&amp;P 500 held near 2,450. While the bulls remain in control in the short-term, we continue to believe the broad equity market is not yet out of the woods and remains vulnerable -- particularly as Wall Street sentiment has flipped bullish. In today’s report we highlight attractive stocks from a relative strength perspective across Sectors.</p>

Continued encouraging COVID-19 news and accommodative moves by the Fed have allowed the bulls to remain in control while short-term support on the S&amp;P 500 held near 2,450. While the bulls remain in control in the short-term, we continue to believe the broad equity market is not yet out of the woods and remains vulnerable -- particularly as Wall Street sentiment has flipped bullish. In today’s report we highlight attractive stocks from a relative strength perspective across Sectors.

U.S. Equity Strategy: Bulls Still In Driver’s Seat, But For How Long?

United States

Chemed Corporation operates in the healthcare field through its subsidiary Vitas Healthcare Corporation.  The Company also maintains a presence in the residential and commercial repair-and-maintenance-service industry under the names Roto-Rooter and Service America Network Inc.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Chemed Corp (CHE US)

Chemed Corporation: A Tale Of Workforce & Patient Expansion To Catalyze Growth! - Major Drivers

Chemed Corporation's management recently their financial results for the first quarter of 2024, which ended on March 31, 2024. The earnings showed...

Baptista Research

Duplicate of Tenet Healthcare Corporation: Initiation Of Coverage - Its Focus on Higher Acuity Services in Hospitals & Other Core Strategies! - Major Drivers

Chemed Corporation reported their fourth quarter 2023 earnings with continued improvement in their VITAS operational metrics, including a 7%...

Baptista Research

Downgrading Utilities & Staples to Market Weight; Buy Ideas in Health Care & Trucking

Positive developments are popping up, such as bullish reversals of 4-5-month downtrends for Financials $XLF and Broker-Dealers/Exchanges $IAI ....

Vermilion Research

Some Easy-To-Grasp Gimmicks to Gauge Management Compensation

Additionally, here are two US-listed mid-cap companies we have been following to illustrate both sides of the management pay matter.

Steven Chen

U.S. Equity Strategy: Bulls Still In Driver’s Seat, But For How Long?

Continued encouraging COVID-19 news and accommodative moves by the Fed have allowed the bulls to remain in control while short-term support on the...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)